Macrogenics (MGNX) Total Non-Current Liabilities (2012 - 2026)

Macrogenics' (MGNX) quarterly Total Non-Current Liabilities came in at $195.9 million in Q1 2026, up 36.57% year-on-year from $143.5 million in Q1 2025, and down 2.13% on a QoQ basis from $200.2 million in Q4 2025.

Macrogenics (MGNX) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends

Macrogenics (MGNX) has 12 years of Total Non-Current Liabilities data on file, last reported at $195.9 million in Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 36.57% year-over-year to $195.9 million in Q1 2026; TTM through Mar 2026 was $195.9 million, a 36.57% increase from a year earlier, with the FY2025 full-year figure at $200.2 million, up 39.39% from the prior year.
  • Total Non-Current Liabilities for Q1 2026 stood at $195.9 million, down from $200.2 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for MGNX reached as high as $234.0 million in Q1 2023 and fell as low as $72.1 million in Q3 2022.
  • Historically, Total Non-Current Liabilities has averaged $150.0 million across 5 years, with a median of $143.6 million in 2024.
  • Across the five-year window, Total Non-Current Liabilities surged 151.66% in 2023 and plunged 39.36% in 2024, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $138.2 million in 2022, then increased by 5.32% to $145.5 million in 2023, then fell by 1.32% to $143.6 million in 2024, then soared by 39.39% to $200.2 million in 2025, then dropped by 2.13% to $195.9 million in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $195.9 million in Q1 2026, $200.2 million in Q4 2025, and $202.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Macrogenics 254.43 Mn 187.92 Mn - 195.95 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 195.95 Mn
Dec 31, 2025 200.20 Mn
Sep 30, 2025 202.43 Mn
Jun 30, 2025 197.13 Mn
Mar 31, 2025 143.48 Mn
Dec 31, 2024 143.63 Mn
Sep 30, 2024 144.17 Mn
Jun 30, 2024 143.06 Mn
Mar 31, 2024 141.87 Mn
Dec 31, 2023 145.55 Mn
Sep 30, 2023 145.73 Mn
Jun 30, 2023 133.85 Mn
Mar 31, 2023 233.97 Mn
Dec 31, 2022 138.20 Mn
Sep 30, 2022 72.13 Mn
Jun 30, 2022 75.30 Mn
Mar 31, 2022 92.97 Mn
Dec 31, 2021 95.37 Mn
Sep 30, 2021 100.46 Mn
Jun 30, 2021 106.61 Mn